2026³â 06¿ù 24ÀÏ ¼ö¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Center for Disease Analysis Foundation Receives $7 Million Grant from the John C. Martin Foundation to Support the Polaris Observatory

´º½ºÀÏÀÚ: 2024-11-22

LAFAYETTE, COLO. -- The Center for Disease Analysis (CDA) Foundation announced receipt of a $7 million grant from the John C. Martin Foundation to sustain and expand the Polaris Observatory until the end of 2030.

The Polaris Observatory serves as the definitive source for global data on hepatitis B and C virus (HBV and HCV) burden, providing insights into the prevalence and distribution of these viruses across countries, regions, and globally. It also assists national governments and international organizations in monitoring progress toward the World Health Organization’s (WHO) 2030 elimination targets for HBV and HCV. Annually, the Observatory collaborates with over 1,000 national experts in 120 countries, updating forecasts for each country. Additionally, it offers pro bono support to national governments, assisting them in developing and implementing elimination programs and strategies to fund for their initiatives.

“We are deeply grateful for the John C. Martin Foundation’s unwavering support,” expressed Homie Razavi, Managing Director of the CDA Foundation. “Their initial funding in 2015 catalyzed the establishment of the Polaris Observatory, and their continuous support has enabled us to sustain our work. The Observatory’s programs are supported by a dedicated team of epidemiologists, mathematical modelers, programmers, and decision analysts. The Observatory’s contributions have resulted in nationally funded access to hepatitis screening for 1.7 billion people globally, laboratory testing (24 million people), and treatment (19 million people) as result of recognized value of early detection and treatment. This new grant will facilitate our continued efforts through 2030.”

“On behalf of the John C. Martin Foundation, it is a privilege to support the CDA Foundation in the past decade to service the international hepatitis elimination collaborators. We are grateful for the opportunity to support such an impactful and momentous program,” said Dr. Lillian Lou, President, Program Director of the John C. Martin Foundation (https://thejcmfoundation.org).

CDA Foundation is a nonprofit organization focused on accelerating hepatitis B and C elimination through verified epidemiological data, disease burden and economic impact modeling, intervention strategies, innovative financing, and knowledge-sharing partnerships. It accomplishes these goals through the Polaris Observatory (https://cdafound.org/polaris/).



 Àüü´º½º¸ñ·ÏÀ¸·Î

Boomi to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across Enterprise
Prokarium Reports Positive Interim PARADIGM-1 Data of ZH9 in NMIBC, Showing Excellent Safety and Early Efficacy
Variational Secures ~$50M to Bring Liquidity from Traditional Markets To Crypto
LTM Launches BlueVerse¢â for iRun to Outcreate Managed Services in the Agentic AI Era
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand
NIQ Research Reveals New Rules of Commerce: AI Is Beginning to Decide What Consumers Buy
Boomi Unveils Innovations That Power the Agentic Enterprise

 

Samsung Bioepis Launches Ustekinumab Biosimilar, Marking Its First Pro...
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60...
Telehouse Canada Undergoes Major Infrastructure Upgrade to Scale AI-Dr...
Enterprise AI Hits the Wall: NTT DATA Research Reveals Growing Privacy...
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agen...
Boomi and Red Hat Collaborate on Production-Ready Agentic AI
Medisca and dsm-firmenich Partner to Expand Access to Pharma-Grade Vit...

 


°øÁö»çÇ×
¹Ìµð¾î¿Í M• Mediaour ØÚ体ä² ØÚô÷ä² ¿¥¿À MO ØÚä²
¾Ë¸®¾Ë A⋮⋮⋮ Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
À£ÇÁ·Ò W⋮⋮⋮ Welfrom 卫ÜØ êÛÝ£
¹ÙÀÌ¿ÀÀÌ´Ï B⋮ BIOINI ù±药研 ¹ÙÀÌ¿ÀÀÌ´Ï·¦ BIOINILAB ...
º£³×ÀÍ ¡Õ Beneik 宝Ò¬ìÌ, À̺ñÁî eBizh æ¶币òª EZ æ¶òª
¿¡³ÊÀÌÀ¯ ¡Õ¡Õ EnerEU 额Òö äþÒö
´º½ºÁö Áß¹®Ç¥±â´Â À½Â÷ Ç¥±â¹æ½Ä '纽ÞÙó¢ ´Ï¿ì½ºÁö'
¾Ë¸®À¯ºñ ^v Alliuv ä¹备 AV ä¹êó备, ¾Ë¶ã =^= Althle ä¹÷åìÌ
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º ¡ÕC À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¾ËÇÁ·Ò ^ Alfrom ä¹尔ÜØ ä¹ì³ÜØ, ¿ÃÇÁ·Ò A⋮⋮ Allfrom &...

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..